Ensign Peak Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Ensign Peak Advisors’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-180,219	Closed	-$7.09M	–	1786
2023 Q2	$7.09M	Sell	180,219 -331,996	-65%	-$11.7M	0.01%	503
2023 Q1	$12.5M	Buy	512,215 +6,050	+1%	+$132K	0.03%	366
2022 Q4	$10.8M	Sell	506,165 -120,459	-19%	-$2.57M	0.02%	390
2022 Q3	$11.2M	Buy	626,624 +185,886	+42%	+$2.44M	0.03%	359
2022 Q2	$4.24M	Buy	440,738 +232,806	+112%	+$2.92M	0.01%	583
2022 Q1	$3.5M	Buy	207,932 +69,243	+50%	+$1.02M	0.01%	689
2021 Q4	$2.32M	Buy	138,689 +51,892	+60%	+$851K	﹤0.01%	908
2021 Q3	$1.41M	Buy	+86,797	New	+$945K	﹤0.01%	1287

Ensign Peak Advisors's ISEE Position: Q3 2023 in Review

Ensign Peak Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 180,219 shares — an estimated $7.09M sold.

Ensign Peak Advisors first reported a position in ISEE in Q3 2021 and held it in 8 quarters. The position peaked at $12.5M in Q1 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

Ensign Peak Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Ensign Peak Advisors sold 180,219 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $7.09M.
Ensign Peak Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Ensign Peak Advisors's IVERIC bio, Inc. Common Stock position peaked at $12.5M in Q1 2023.
0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on Ensign Peak Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.